

# Impact of iloprost on early graft viability after liver transplantation

**Submission date**  
31/07/2008

**Recruitment status**  
No longer recruiting

Prospectively registered

Protocol

**Registration date**  
09/10/2008

**Overall study status**  
Completed

Statistical analysis plan

Results

**Last Edited**  
27/09/2017

**Condition category**  
Injury, Occupational Diseases, Poisoning

Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Erik Bärthel

**Contact details**  
Department of General Visceral and Vascular Surgery  
University Hospital of Jena  
Jena  
Germany  
07740

## Additional identifiers

## Study information

**Scientific Title**  
Impact of iloprost on early graft viability after liver transplantation: a randomised controlled trial

**Study objectives**  
Improved graft viability under treatment with systemically administered prostacyclin analogue iloprost.

**Ethics approval required**  
Old ethics approval format

## **Ethics approval(s)**

Ethics Committee of Medical Faculty, Friedrich Schiller University of Jena (Ethik-Kommission der Friedrich-Schiller-Universität Jena an der Medizinischen Fakultät). Date of approval: 20/06/2006 (ref: 1765-04/06)

## **Study design**

Prospective randomised controlled trial

## **Primary study design**

Interventional

## **Study type(s)**

Treatment

## **Health condition(s) or problem(s) studied**

Liver transplantation

## **Interventions**

A prospective, randomised, single-center study. Patients of the treatment group received 1 ng /kg body weight /min iloprost (BayerVital AG Berlin, Germany), systemically administered for 7 days post-liver transplantation, in contrast to the control (no treatment) population. Peak levels of transaminases (aspartate aminotransferase [ASAT]/alanine aminotransferase [ALAT]), factor V, quick's value, bile production and the indocyanine green plasma disappearance rate (ICG-PDR), were determined continuously. Furthermore, the arterial resistance index (RI) as parameter of liver perfusion as well as patient and graft survival were evaluated.

## **Intervention Type**

Drug

## **Phase**

Not Applicable

## **Drug/device/biological/vaccine name(s)**

Iloprost

## **Primary outcome(s)**

Incidence of primary graft dysfunction within 48 hours postoperatively.

## **Key secondary outcome(s)**

1. Rate of re-transplantation caused by initial graft non-function within 48 hours postoperatively
2. Time of hospitalisation (duration of follow-up depends on the circumstances of each patient)
3. Length of stay in intensive care unit (duration of follow-up depends on the circumstances of each patient)
4. Rate of complications due to biliary tract lesions within 1-year follow-up

## **Completion date**

01/09/2008

## **Eligibility**

**Key inclusion criteria**

1. Aged over 18 years, either gender
2. Full size orthotop liver transplantation

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Lower age limit**

18 years

**Sex**

All

**Key exclusion criteria**

1. Circulatory instability
2. Noradrenaline doses  $>0.5 \mu\text{g}/\text{kg}$  body weight/min
3. Pregnancy
4. Known intolerance of iloprost

**Date of first enrolment**

01/09/2006

**Date of final enrolment**

01/09/2008

**Locations****Countries of recruitment**

Germany

**Study participating centre**

Department of General Visceral and Vascular Surgery

Jena

Germany

07740

**Sponsor information****Organisation**

University Hospital of Jena (Universitätsklinikum Jena) (Germany)

**ROR**

<https://ror.org/035rzkx15>

## Funder(s)

**Funder type**

Hospital/treatment centre

**Funder Name**

University Hospital of Jena (Germany)

## Results and Publications

**Individual participant data (IPD) sharing plan**

**IPD sharing plan summary**

Not provided at time of registration

**Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results of pilot study	01/01/2012		Yes	No